Bringing the Future of Hematology 100X Closer

Partners in Innovation

In this SelectScience interview from AACC 2022, Peter Soltani, Senior VP at Beckman Coulter, and Itai Hayut, co-founder and CEO at Scopio Labs, discuss how Scopio’s AI-powered workflow solution is changing hematology imaging and share their excitement around the new partnership.

The increasing worldwide prevalence of hematological disorders and malignancies is exponentially increasing the required amount of diagnostic testing¹ making the importance of early diagnosis and effective treatment initiation more important than ever. Understanding blood cellular morphology adds to the value of a routine blood count and can help to identify hematologic disorders. Traditionally, peripheral blood smear (PBS) analysis has been performed manually. To improve both speed and accuracy, however, we need to lean in to technology – especially as laboratorians and clinicians are already required to do more with fewer people and resources.

Scopio Labs is advancing global hematology diagnostics with their regulatory-cleared digital imaging platforms and Full-Field Peripheral Blood Smear™ (FF-PBS) application, a fully digitized cell morphology platform. FF-PBS allows for high-resolution imaging over the entirety of the clinically-relevant slide – from the monolayer to the feathered edge – for a fully digital image that eliminates the need for manual microscopy. Incorporating AI into the platform saves time and aids in clinical diagnosis by pre-classifying cells prior to expert review.

Digitalization of hematology slides is tranforming cell morphology analysis and changing how scientists work both inside and outside the lab. Because the samples are fully digital, clinicians and lab professionals have the ability to analyze samples from anywhere in their hospital's secure network, supporting more collaboration and faster review.

We’re thrilled to add this ground-breaking technology to our suite of innovative hematology solutions.

Watch interview